Amgen Inc. et al. v. Bristol-Myers Squibb Company

IPR2025-00601

Amgen’s request for Director Review of IPR denial is rebuffed by Bristol‑Myers Squibb, which argues the petitioner offers no credible basis and that European prosecution does not affect settled expectations for the U.S. patent.

Jurisdiction
US PTAB
Case Number
IPR2025-00601
Filing Date
28 February 2025
Status
ok

Related Cases

patentPGR2025-00011

Phison Electronics CorporationvsVervain, LLC

Phison Electronics has filed a post‑grant review petition seeking cancellation of Vervain’s 11,830,546 NAND‑flash patent. The petitioner alleges the claims are abstract, lack written description, are indefinite, and are obvious over prior art. The Board must decide whether to institute the review.

patentIPR2024-00708

DELL INC. et al.vsAX Wireless, LLC et al.

Dell and AX Wireless have jointly moved to terminate the IPR over patent 11,212,146 after reaching a settlement. The motion cites statutory authority for termination and notes that the Board has not yet decided the merits.

patentIPR2024-00556

Valve CorporationvsImmersion Corporation

The PTAB granted institution of IPR for Valve Corporation against Immersion Corporation regarding patent 8,749,507. The Board found a reasonable likelihood that claims are obvious in view of Astala and Shahoian, and Keely/Kolmykov-Zotov.

patentIPR2025-01104

Ascentcare Dental Products, Inc.vsSolmetex, LLC

Ascentcare Dental Products has petitioned the PTAB to invalidate claims 1‑4 and 7‑18 of Solmetex’s 11,589,970 patent, alleging obviousness over several prior‑art dental mouthpiece references. The petition seeks institution of an IPR and cancellation of the challenged claims.

patentIPR2024-00442

Comcast Corporation et al.vsEntropic Communications LLC

Comcast Cable Communications successfully argued that multiple claims in the patent were obvious under 35 U.S.C. § 103, leading to an institution decision by the PTAB. The Board found a reasonable likelihood of prevailing on the assertions of obviousness across various combinations of prior art references.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call